Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $42.00 to $28.00. They now have a "buy" rating on the stock.
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.